These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37126754)

  • 1. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
    Bond AM; Dean EB; Desai SM
    Health Aff (Millwood); 2023 May; 42(5):632-641. PubMed ID: 37126754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
    Dean EB; Johnson P; Bond AM
    JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals.
    Li Y; Xu S
    JAMA Netw Open; 2022 Feb; 5(2):e220045. PubMed ID: 35179584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
    Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
    Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.
    Qian J
    J Manag Care Spec Pharm; 2021 May; 27(5):660-666. PubMed ID: 33908273
    [No Abstract]   [Full Text] [Related]  

  • 11. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
    Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
    Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs.
    Chang J; Karaca-Mandic P; Nikpay S; Jeffery MM
    JAMA Health Forum; 2023 Jun; 4(6):e231485. PubMed ID: 37351874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US Hospital Service Availability and New 340B Program Participation.
    Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
    JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan K; Romley JA; Myerson R
    BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.
    Karaca-Mandic P; Chang J; Go R; Schondelmeyer S; Weisdorf D; Jeffery MM
    Health Aff (Millwood); 2019 Nov; 38(11):1887-1892. PubMed ID: 31682491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
    Liu A; Xuan A; Socal M; Anderson G; Anderson KE
    J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
    Conti RM; Bach PB
    Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.